Guanidinopropionic acid
Appearance
Names | |
---|---|
IUPAC name
3-Carbamimidamidopropanoic acid[1]
| |
Other names
3-(Diaminomethylideneamino)propanoic acid[citation needed]
| |
Identifiers | |
3D model (JSmol)
|
|
3DMet | |
1705262 | |
ChEBI | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.005.937 |
EC Number |
|
KEGG | |
MeSH | guanidopropionic+acid |
PubChem CID
|
|
RTECS number |
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C4H9N3O2 | |
Molar mass | 131.135 g·mol−1 |
Appearance | White crystals |
Odor | Odourless |
log P | −1.472 |
Acidity (pKa) | 4.219 |
Basicity (pKb) | 9.778 |
Hazards | |
GHS labelling: | |
Warning | |
H315, H319, H335 | |
P261, P305+P351+P338 | |
Related compounds | |
Related alkanoic acids
|
|
Related compounds
|
Dimethylacetamide |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
β-Guanidinopropionic acid, also referred to as guanidinopropionic acid, beta-guanidinopropionic acid or β-GPA, is a dietary supplement.
β-Guanidinopropionic acid, also known as Ompenaclid (RGX-202), is being investigated in colorectal cancer by Inspirna and Merck[2]
β-Guanidinopropionic acid is a white crystalline powder soluble in water (50 mg/ml-clear, colorless solution).[3]
Studies on animals (rats, monkeys, hamsters) show that acidic guanidine derivatives such as β-GPA can ameliorate hyperglycemia in animal models of noninsulin-dependent diabetes.[4]
Though the oral availability of β-GPA is well established, the basic uptake mechanism has not been studied yet.[5]
References
[edit]- ^ "3-guanidinopropanoic acid (CHEBI:15968)". Chemical Entities of Biological Interest. UK: European Bioinformatics Institute. 20 July 2010. Main. Retrieved 26 April 2012.
- ^ "Pipeline – Inspirna". inspirna.com. Retrieved 2024-11-12.
- ^ Bergeron, R.; Ren, J. M.; Cadman, K. S.; Moore, I. K.; Perret, P.; Pypaert, M.; Young, L. H.; Semenkovich, C. F.; Shulman, G. I. (2001). "Chronic Activation of AMP Kinase Results in NRF-1 Activation and Mitochondrial Biogenesis". American Journal of Physiology. Endocrinology and Metabolism. 281 (6): E1340–E1346. doi:10.1152/ajpendo.2001.281.6.e1340. PMID 11701451. S2CID 21577702.
- ^ Meglasson, M. D.; Wilson, J. M.; Yu, J. H.; Robinson, D. D.; Wyse, B. M.; de Souza, C. J. (September 1993). "Antihyperglycemic Action of Guanidinoalkanoic Acids: 3-Guanidinopropionic Acid Ameliorates Hyperglycemia in Diabetic KKAy and C57BL6Job/ob Mice and Increases Glucose Disappearance in Rhesus Monkeys". The Journal of Pharmacology and Experimental Therapeutics. 266 (3): 1454–1462. PMID 8371149.
- ^ Metzner, L.; Dorn, M.; Markwardt, F.; Brandsch, M. (April 2009). "The Orally Active Antihyperglycemic Drug β-Guanidinopropionic Acid is Transported by the Human Proton-Coupled Amino Acid Transporter hPAT1". Molecular Pharmaceutics. 6 (3): 1006–1011. doi:10.1021/mp9000684. PMID 19358571.